#pharmaceutical-patents
#pharmaceutical-patents

[ follow ]

USPTO Study into Applications with Large Patent Families Raises Questions

The USPTO study revealed widespread use of terminal disclaimers and amendments in response to omitted double patenting rejections.

Concerns over 'patent thickets' in pharmaceuticals led to a five-year study by the USPTO.

The Inflation Reduction Act's drug price negotiations are criticized as price fixing rather than true negotiations.

[ Load more ]